$6.02+0.01 (+0.17%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Ocular Therapeutix (OCUL) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue fell 18.5% in FY25, net margin −511.9%. Worth your attention in FY25: Share count (+127.9%) and Capex step-up ($12.0M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼18.5%
52.0
FY21→FY25CAGR +4.5%/yr
Net income ($M)▼37.4%
−265.9
FY21→FY25CAGR —
Free cash flow ($M)▼59.5%
−216.9
capex stepped upCAGR —
Diluted EPS▼16.4%
−1.42
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+127.9%
82.2mn → 187.2mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$12.0M
▲832% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-512¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 89.9% → 87.3%. Net margin -511.9% is below the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 50.4 | 52.0 | 63.7 | 58.4 | 51.5 | 43.5 | ▼18.5% | +4.5% |
Cost of revenue | 6.4 | 6.6 | 5.6 | 5.3 | 4.5 | 4.4 | ▲16.9% | +10.5% |
Gross profit | 44.0 | 45.4 | 58.1 | 53.2 | 47.0 | 39.1 | ▼21.9% | +3.8% |
Research & development | 245.9 | 197.1 | 127.6 | 61.1 | 53.5 | 50.1 | ▲54.4% | +40.8% |
Selling, general & admin | 78.7 | 64.4 | 60.7 | 33.9 | 32.2 | 31.9 | ▲6.1% | +19.2% |
Total operating expenses | 387.1 | 315.4 | 229.9 | 135.5 | 125.6 | 117.2 | ▲37.2% | +28.1% |
Operating incomefeeds ROC rank | −343.1 | −270.0 | −171.8 | −82.4 | −78.7 | −78.0 | ▼57.2% | — |
Other income, net | 16.2 | 4.0 | −21.7 | 1.6 | 7.6 | 71.5 | — | — |
Pretax income | −326.8 | −266.0 | −193.5 | −80.7 | −71.0 | −6.6 | ▼37.4% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −326.8 | −265.9 | −193.5 | −80.7 | −71.0 | −6.6 | ▼37.4% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −1.44 | −1.42 | −1.22 | −1.02 | −0.97 | −0.98 | ▼16.4% | — |
Diluted shares (mn) | 225.52 | 187.24 | 158.27 | 85.60 | 82.64 | 82.16 | ▲18.3% | +22.9% |
| Margins | ||||||||
Gross margin82nd pct in Healthcare | 87.3% | 87.3% | 91.2% | 91.0% | 91.2% | 89.9% | ▼3.8pp | −2.5pp |
Operating margin | −680.9% | −519.8% | −269.6% | −141.0% | −152.7% | −179.3% | ▼250.2pp | −340.4pp |
Net margin5th pct in Healthcare | −648.6% | −511.9% | −303.7% | −138.1% | −138.0% | −15.1% | ▼208.2pp | −496.8pp |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium, and 9 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-05 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Ocular Therapeutix's revenue last fiscal year?
Ocular Therapeutix reported revenue of $52.0M in fiscal 2025, down 18.5% from fiscal 2024.
What was Ocular Therapeutix's net income?
Ocular Therapeutix reported net income of −$265.9M in fiscal 2025, a net margin of −511.9%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

